INM · Inmed Pharmaceuticals Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '25 | Q2 '24 | Q1 '24 | Q2 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | $820.2K | $1.12M | $1.11M | $1.17M | $1.26M | $1.24M | $901.9K | $469.8K | $1.03M |
| Cost of Revenue | - | $636.0K | $717.0K | $650.8K | $883.1K | $771.2K | $745.6K | $787.7K | $338.6K | $841.4K |
| Gross Profit | - | $184.2K | $403.2K | $460.9K | $289.5K | $493.4K | $324.1K | $21.2K | $131.2K | $192.5K |
| R&D | $1.02M | $630.6K | $581.6K | $1.06M | $656.8K | $771.2K | $609.8K | $1.29M | $851.4K | $878.3K |
| SG&A | $1.74M | $1.62M | $1.53M | $1.55M | $1.37M | $1.42M | $1.36M | $1.30M | $1.46M | $1.41M |
| Total Operating Expenses | $2.84M | $2.29M | $2.22M | $2.71M | $2.13M | $2.23M | $1.97M | $2.69M | $2.37M | $2.34M |
| D&A | $51.7K | $53.2K | $53.2K | $53.2K | $54.8K | $54.6K | $55.2K | $54.8K | $49.0K | $50.7K |
| Operating Income | ($2.79M) | ($2.03M) | ($1.73M) | ($2.58M) | ($1.72M) | ($1.68M) | ($1.48M) | ($2.54M) | ($2.10M) | ($2.00M) |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | - | - | - | - | - | - | - | $6.8K | - | - |
| Net Income | ($2.97M) | ($2.03M) | ($1.73M) | ($2.58M) | ($1.72M) | ($1.68M) | ($1.48M) | ($2.54M) | ($2.10M) | ($2.00M) |
| EPS - Basic | ($0.73) | ($0.51) | ($0.44) | ($3.64) | ($3.58) | ($2.71) | ($3.80) | ($15.20) | ($154.60) | ($12.00) |
| EPS - Diluted | ($0.73) | ($0.51) | ($0.44) | ($3.64) | ($3.58) | ($2.71) | ($3.80) | ($15.20) | ($154.60) | ($122.80) |
Balance Sheet
| Line item | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '25 | Q2 '24 | Q1 '24 | Q2 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $5.16M | $6.95M | $9.33M | $11.08M | $4.68M | $5.58M | $6.57M | $6.74M | $8.91M | $9.60M |
| Accounts Receivable | - | $183.0K | $343.5K | $465.1K | $367.8K | $284.7K | $352.8K | $165.8K | $260.4K | $170.3K |
| Inventory | - | $947.9K | $890.8K | $961.2K | $814.0K | $1.22M | $1.24M | $1.13M | $1.62M | $1.33M |
| Accounts Payable | $225.1K | $166.8K | $369.1K | $370.1K | $559.8K | $2.0K | $41.0K | $379.9K | $544.2K | $737.5K |
| Current Assets | $6.89M | $8.79M | $10.80M | $12.87M | $6.41M | $7.28M | $8.69M | $8.30M | $11.33M | $11.84M |
| Total Assets | $9.13M | $11.19M | $13.36M | $15.58M | $9.28M | $10.47M | $11.82M | $10.92M | $14.11M | $14.73M |
| Current Liabilities | $2.21M | $1.48M | $1.55M | $1.84M | $1.84M | $1.44M | $1.97M | $1.34M | $2.00M | $2.27M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $2.24M | $1.60M | $1.77M | $2.15M | $2.26M | $2.07M | $2.62M | $1.34M | $2.02M | $2.34M |
| Stockholders' Equity | $6.89M | $9.59M | $11.59M | $13.43M | $7.02M | $8.40M | $9.21M | $9.58M | $12.09M | $12.39M |
| Retained Earnings | ($123.96M) | ($120.99M) | ($118.96M) | ($117.24M) | ($115.45M) | ($110.75M) | ($109.08M) | ($103.94M) | ($101.40M) | ($101.06M) |
Cash Flow
| Line item | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '25 | Q2 '24 | Q1 '24 | Q2 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | ($1.61M) | - | - | ($1.83M) | - | ($2.17M) | - | - |
| Investing Cash Flow | - | - | - | - | - | - | - | - | - | - |
| Financing Cash Flow | - | - | ($137.2K) | - | - | $838.2K | - | - | - | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q2 '25 | Q3 '25 | Q1 '25 | Q2 '24 | Q1 '24 | Q2 '23 | Q3 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | 22.5% | 36.0% | 41.5% | 24.7% | 39.0% | 26.1% | 2.4% | 27.9% | 18.6% |
| Operating margin | - | -247.3% | -154.2% | -231.6% | -146.9% | -132.7% | -119.2% | -281.3% | -447.2% | -193.2% |
| EBITDA margin | - | -240.8% | -149.4% | -226.8% | -142.3% | -128.4% | -114.7% | -275.2% | -436.8% | -188.3% |
| Net margin | - | -247.3% | -154.2% | -231.6% | -146.9% | -132.7% | -119.2% | -281.3% | -447.2% | -193.2% |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | 76.9% | 51.9% | 95.4% | 56.0% | 61.0% | 49.2% | 143.3% | 181.2% | 84.9% |
| SG&A / Revenue | - | 197.6% | 136.8% | 139.7% | 117.2% | 112.4% | 110.0% | 144.0% | 311.8% | 136.6% |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -32.5% | -18.1% | -12.9% | -16.5% | -18.6% | -16.0% | -12.5% | -23.2% | -14.9% | -13.6% |
| Return on equity | -43.0% | -21.2% | -14.9% | -19.2% | -24.5% | -20.0% | -16.1% | -26.5% | -17.4% | -16.1% |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 3.11 | 5.94 | 6.95 | 6.99 | 3.49 | 5.07 | 4.41 | 6.19 | 5.66 | 5.22 |
| Quick ratio | 3.11 | 5.30 | 6.37 | 6.47 | 3.04 | 4.22 | 3.78 | 5.35 | 4.86 | 4.63 |
| Cash ratio | 2.33 | 4.70 | 6.00 | 6.02 | 2.54 | 3.89 | 3.33 | 5.03 | 4.45 | 4.23 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.33 | 1.17 | 1.15 | 1.16 | 1.32 | 1.25 | 1.28 | 1.14 | 1.17 | 1.19 |
| Liabilities / Assets | 0.25 | 0.14 | 0.13 | 0.14 | 0.24 | 0.20 | 0.22 | 0.12 | 0.14 | 0.16 |
| Efficiency | ||||||||||
| Asset turnover | - | 0.07 | 0.08 | 0.07 | 0.13 | 0.12 | 0.10 | 0.08 | 0.03 | 0.07 |
| Inventory turnover | - | 0.67 | 0.80 | 0.68 | 1.08 | 0.63 | 0.60 | 0.70 | 0.21 | 0.63 |
| Days sales outstanding | - | 81d | 112d | 153d | 114d | 82d | 104d | 67d | 202d | 60d |
| Days inventory outstanding | - | 544d | 454d | 539d | 336d | 577d | 609d | 525d | 1742d | 577d |
| Days payable outstanding | - | 96d | 188d | 208d | 231d | 1d | 20d | 176d | 587d | 320d |
| Cash conversion cycle | - | 530d | 378d | 484d | 220d | 659d | 693d | 416d | 1358d | 317d |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 0.4x | 0.4x | 0.7x | 0.2x | 0.1x | 0.4x | 4.6x | 4.9x | 3.5x | 5.8x |
| P / S | - | 5.1x | 7.7x | 2.1x | 0.8x | 2.3x | 34.2x | 51.7x | 90.8x | 69.5x |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | -26.2% | -11.4% | -10.4% | - | 40.2% | 164.0% | 181.1% | 77.2% | 234.0% |
| Revenue CAGR (3y) | - | 20.4% | 51.7% | 61.3% | 55.9% | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | -60.0% | -18.3% | 42.2% | - | 2222.8% | 147.1% | - | 17.6% | 5.6% |
| Operating income growth (YoY) | -62.0% | 21.2% | -2.9% | -74.2% | - | 33.9% | 29.6% | 27.7% | 6.4% | 42.5% |
| Net income growth (YoY) | -72.2% | 21.2% | -2.9% | -74.2% | - | 33.9% | 29.6% | 27.7% | 50.9% | 42.5% |
| EPS growth (YoY) | 79.6% | 86.0% | 83.8% | 4.2% | - | 82.2% | 97.5% | -274.4% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -1.8% | -28.6% | 38.1% | 45.9% | - | -12.3% | -23.9% | -13.0% | 33.2% | 13.8% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2024-06-30.
Business segments
$4.60M totalBay Medica Commercial$4.60M · 100.0%
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing InMed Pharmaceuticals Inc. against the 5 most active filers in the same SIC group.